CTRI/2020/03/023951尚未招募4 期
A prospective, randomized, triple-blind comparative study of ropivacaine-dexmedetomidine versus ropivacaine alone in peribulbar blocks
Gayatri vidya parishad Institute of health care and medical technology0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion criteria for our study consist of both male and female patients with an age range between 40 and 80 years and are of American Society of Anesthesiologists (ASA) physical status grades I and II attending our medical college hospital for elective cataract surgery.
排除标准
- •The exclusion criteria for our study include patients with known allergy to study drugs, those refusing the regional block, those on anticoagulant therapy, high myopia (axial length of eyeball > 28 mm), previous ophthalmic surgery such as buckling surgery, glaucoma, posterior staphyloma, ocular infection, orbital anomaly, mental retardation, uncontrolled hypertension & diabetes mellitus, and chronic obstructive pulmonary disease.
研究者
相似试验
尚未招募
4 期
Ropivacaine versus bupivacaine plus lidocaine in peribulbar blocksCTRI/2021/08/035884Gayatri vidya parishad Institute of health care and medical technology
已完成
不适用
A clinical study to assess the safety and effectiveness of collagen-containing test products in healthy adult Human subjectsCTRI/2022/11/047566Bright LifeCare Private Limited56
进行中（未招募）
1 期
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-GBGlaxoSmithKline Biologicals1,220
进行中（未招募）
1 期
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-DEGlaxoSmithKline Biologicals1,220
进行中（未招募）
1 期
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageVaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).MedDRA version: 18.1Level: PTClassification code 10069613Term: Varicella immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10069628Term: Varicella immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10063315Term: Varicella zoster virus DNA test positiveSystem Organ Class: 100000004848MedDRA version: 18.0Level: LLTClassification code 10046983Term: Varicella zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: PTClassification code 10046980Term: VaricellaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: LLTClassification code 10050331Term: Varicella-like rashSystem Organ Class: 100000004858MedDRA version: 18.0Level: LLTClassification code 10063144Term: Varicella zoster virus serology positiveSystem Organ Class: 100000004848EUCTR2013-003535-30-EEGlaxoSmithKline Biologicals1,220